AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

✍ Scribed by F Barlesi; J. de Castro; V. Dvornichenko; J.H. Kim; A. Pazzola; A. Rittmeyer; A. Vikström; L. Mitchell; E.K. Wong; V. Gorbunova

• Book ID: 117660632
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 48 KB
• Volume: 47
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(11)70133-2